Theratechnologies appoints new ceo

John-Michel Huss has more than 20 years’ experience in the pharmaceutical industry

Theratechnologies, a Canadian biopharmaceutical company based in Montreal, has appointed John-Michel Huss as president and chief executive.

Until recently, Huss was chief of staff, in the office of the ceo, at Sanofi-Aventis in Paris. He has more than 20 years’ experience in the pharmaceutical industry in various international positions and was responsible for various disease areas including diabetes and metabolism.

Huss began his career in 1990, at Merck & Co, primarily in sales and marketing in the US, Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an internal product manager at its Basel headquarters in Switzerland. From there in 1999, he joined Sanofi-Synthélabo as business unit director and has held various positions of increasing responsibility in marketing and sales. He became general manager in Switzerland in 2007.

During his tenure at Sanofi-Aventis (Sanofi-Synthélabo merged with Aventis in 2004) Huss held positions in Germany, Canada, Switzerland and France.

‘I am honoured to have been chosen as Theratechnologies' president and ceo,’ said Huss.

‘The company has done an outstanding job of developing an exciting new compound, tesamorelin, and navigating it through the final regulatory stages of the drug development process.’

You may also like

Research & Development

Theratechnologies to cut 24 jobs in r&d restructure

Aims to strengthen its growth potential
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Research & Development

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena
Manufacturing

WLS introduces PR-12 and PR-24 plunger rod insertion and labelling systems

By improving reliability and streamlining production, the PR-12 and PR-24 help pharmaceutical manufacturers and contract packers protect product quality and reduce waste while maximising operational efficiencies
Subscribe now